

Background :

Cholangiocarcinoma (CCA) is prevalent in the Greater Mekong Subregion, especially in northeastern Thailand and Lao PDR, where the liver fluke *Opisthorchis viverrini* is endemic. Most patients with CCA are diagnosed at an advanced stage, resulting in limited survival times post-surgery due to the absence of reliable biomarkers. Currently, CCA diagnosis relies on radiological and histopathological techniques, which are both expensive and time-consuming. Our research has identified numerous biomarkers for CCA in animal models, which have been successfully adapted for clinical applications in patients. The emergence of biosensor platforms, utilizing photonic and electrochemical detection technologies, offers a significant advantage due to their high integration capabilities. This advancement facilitates the transition of these tools from research laboratories to practical use in analytical chemistry and clinical medicine, allowing large-scale detection across various sample types, including urine, feces, and serum. We hypothesize that the deployment of these biosensor platforms for detecting trace levels of CCA biomarkers in animal models has the potential to be translated effectively into clinical applications for patient diagnosis.

Targets:

To develop photonic and electrochemical biosensors for cholangiocarcinoma diagnosis.

Speaker:

Dr. Somchai Pinlaor, Dr. Chavis Srichan, Dr. Pobporn Danvirutai

Project Members :



KKU (THA) : **Somchai Pinlaor**, Chavis Srichan, Pobporn Danvirutai, Kitti Intuyod, Apisit Chaidee, Sirinapha Klungsaeng



CMU (THA) : Ukrit Mankong, Suruk Udomsom

TMEC : Nithi Atthi



BIOTECH : Sittiruk Roytrakul, Janthima Jaresitthikunchai, Narumon Phaonakrop

NECTEC : Noppadon Nuntawong, Mati Horprathum, Pitak Eiamchai, Saksorn Limwichean



Mittaphab Hospital (LAO) : Champadeng Vongdala, Keooudone Thammavong

NICT (JPN) : Toshimasa Umezawa, Atsushi Matsumoto, Kouichi Akahane

Project Duration : 24 months

First Year : May 1st , 2023 to April 30th , 2024

Second Year: May 1st , 2024 to April 30th , 2025

Project Budget: 80,000 USD

First Year : 40,000 USD

Second Year: 40,000 USD



Old hypothesis

***O. viverrini* infection contributes to CCA development**




Fig.1 *OV*-induced inflammation, fibrosis, advanced fibrosis, and contribution risk to CCA. Thus, radiology such as MRI & Ultrasound are used for CCA screening.

New hypothesis




Fig.2 *OV*-induced chronic inflammation, precancerous lesion and CCA development




Fig.3 Schematic diagram illustration of the scope of the study in animal model. The early marker for CCA diagnosis was discovered in hamster model and apply in the patients. The step include 1) proteomic analysis for protein identification, 2) Raman spectroscopy based on based line peak, SERS from NECTEC and SERS from EN-KKU, and 3) histopathological study by staining with hematoxylin-eosin (H&E), cytokeratin-19 (CK-19) and alpha-fetoprotein (AFP).




Fig.4 CCA development is classified into inflammation, pre-cancerous lesion and tumor lesion according to histopathological changes




Fig.5 Comparison among principle components analysis (PCA) results of Raman spectra of four classes of normal, inflammation, pre-cancerous and tumor. However, Raman intensities couldn't distinguish between pre-cancerous and CCA groups based on classical machine (ML) algorithm.




Fig.6 Comparison among Raman peak based on classical machine (ML) algorithm of four classes based on normal, inflammation, pre-cancerous and tumor features.

	precision	recall	f1-score	support
Group 1-N	0.61	0.84	0.71	231
Group 2-I	0.40	0.07	0.11	61
Group 3-P	0.61	0.51	0.56	210
Group 4-C	0.65	0.65	0.65	220
accuracy			0.62	722
macro avg	0.57	0.52	0.51	722
weighted avg	0.61	0.62	0.60	722

SERS couple with PCA couldn't distinguish precancerous-tumor lesion and yield accuracy of test 62%.





Fig.7 Different staging of CCA development was established.




Fig.8 Illustration of study design for SERS+AI marks early stage of CCA




Fig.9 Raman peak identifies the different staging of inflammation, precancerous (Pre-CA) and CCA lesions




Fig.10 ROC curves analysis the performance of various classification models. The DWT + 2D CNN model achieved an AUC of 0.95, which gave the highest accuracy performance for CCA diagnosis compared to the other models.




Fig.11 Confusion matrices of each signal processing and machine learning methods by 2D CNN.

Method	Accuracy (%)	Sensitivity (Recall) (%)	Specificity (%)	F1 Score (%)
DWT + 2D CNN	95.10	95.08	98.36	95.10
DWT + 1D CNN	92.00	91.50	96.00	91.75
PCA + 1D CNN	88.00	87.50	94.00	87.75
LDA + SVM	84.50	84.00	90.50	84.25
PCA + SVM	82.40	82.00	88.40	82.20



Accuracy 95%, sensitivity 95%. Specificity 96%

Raman spectrometry coupled with machine learning, especially, 2D CNN, could distinguish stage-specific for CCA development for normal, inflammation, pre-cancerous and tumor, but doesn't by classical machine learning of Raman intensity. Integrative SERS with 2D CNN explores high accuracy performance for early CCA diagnosis, which can apply for a mobile application use.


ENKKU: Biosensing platform based on SERS

1. Biosensing platform development based on Raman spectroscopy techniques

Surface Enhance Raman Spectroscopic (SERS) chip development



enhanced hotspot with linkers and receptors for biomarker




SERS chip using (a) 3D microporous graphene (Srichan *et al.*, 2016) (b) Silver nanorods fabricated by glancing angle method (Botta *et al.*, 2018) (c) electrochemically synthesized silver nanowires (Fang *et al.*, 2012) (d) Hot spot model as one of the mechanisms behind Raman signal enhancement (Radziuk & Moehwald, 2015).

(a) Raman peak selection for a specific analyte (Srichan *et al.*, 2016), (b) designed portable SERS-based sensor for early CCA detection (this proposal).

Preliminary Results

- In literature we sampling peaks before processing SERS signal
- We propose novel technique that use whole spectrum with multiresolution compression and CNNs



Biosensing platform development based on Raman spectroscopy techniques

Surface Enhance Raman Spectroscopic (SERS) chip development





Part I: Synthesis of AuNPs and novel techniques to pair nanoparticles to yield greatest enhancement

Received (see page20)


1 Software license

2 (Tier 1) Paper under intensive peer review [Nature Scientific Reports]

3. (Scopus-index) Conference paper to appear in IEEEXplore





+ carried out characterization on TEMs, SEM, processing technique, etc. (Figures will be licensed under publisher)







Partial Least Squares Discriminant Analysis (PLS-DA) analysis

Normal
Pre-CA
CCA






Heatmap



In progress to verify in human samples

Project activities: MDKKU; Sample collection, identification and evaluation of biomarker in CCA patients



Determination of β -HCG levels in human serum. Serum β -HCG levels in healthy (N=60), Bening biliary disease (N=52), and CCA patient (N=100) were determined using electrochemiluminescence immunoassay. * $P < 0.05$ compared with healthy group. # $P < 0.05$ compared with BBD group.

Immunohistochemical staining for β -hCG in cholangiocarcinoma and adjacent tissues. Staining pattern of the TMA section (A). Immunoreactive positive area (%) in cancerous tissues was higher than in adjacent tissues (B). Images showing β -hCG staining in CCA (C), and adjacent tissues (D). ** $P < 0.001$ compared with adjacent tissue.

Raman peak separates serum CCA from the patients from normal serum by Raman spectroscopy. Upper line is CCA, and under line is normal.






Figure 8. ROC analysis results when combined HCG, AFP, CEA and CA19-9

Project Activities: MDKKU, ENKKU, NECTEC, BIOTECH

Budget usage for the 1st year  COMPLETED

Activities	Budget
Hamsters' CCA setting, samples collection and histopathological confirmation	4,000 USD
Discovery of Raman peak for CCA diagnosis	3,000 USD
Patients sample collection	2,500 USD
Identification & evaluation of biomarker in CCA patients: training set	3,500 USD
Verification of electrochemical sensor for CCA diagnosis: verification set	3,000 USD
SERS development: Synthesis	4,000 USD
SERS development: Characterization	1,000 USD
Total	21,00 USD

Budget usage for the 2nd year 

Activities	Budget
Sample collection and providing standard protein & antibody for CMUs' team	4,000 USD
Proteins panel discovery and identification	7,500 USD
Raman spectrum identification	5,000 USD
Construct AI & Machine learning model	2,000 USD
Transfer technology of SERS and AI for CCA diagnosis to Laos' team	2,500 USD
KKU facilities services	2,100 USD

Total **21,000 USD**

INPROGRESS

Overview of research objectives and activities of CMU

CMU: Biosensing platform based on silicon photonic development



Activities in ASEAN IVO 2023

1. Sensor device design investigation specifically for the detection of CCA biomarker (s)
2. Simulation of silicon nitride biosensor devices

Activities in ASEAN IVO 2024

1. Prototype sensor system development
2. Sensing experiment using samples provided by KKU or Laos
 - Detection of new CCA biomarkers from KKU
 - Comparison with conventional method

(Year 1) Key elements demonstrated in laboratory

Budget usage	Budget	
Survey report of the photonic sensor technologies that are applicable to cholangiocarcinoma detection.	\$3000	✓
investigation of new photonic sensor design and simulation results using numerical based simulation.	\$3000	✓
Computer-aided design (CAD) drawing of silicon photonic sensor mask design	\$1500	✓

(Year 2) Device manufacturing & performance assessment using standard testing method

Budget usage	Budget	
Photonic (resonator) sensor devices and a prototype of the measuring system	\$7000	🕒
Project workshop and meeting	\$3500	🕒



PENDING/ INPROGRESS

Confidential


2024 PROGRESS

CMU: Biosensing platform based on silicon photonic development



Biomedical Engineering Institute
Chiang Mai University

Fabrication of silicon photonic sensors



Photomask designs submitted to manufacturer (TMEC)
August 2024 ✓



Fabricated sensors expected by
December 2024

Development of New sensor measurement system prototype

Proof of concept In Laboratory

broadband source

September 2024 ✓



MEMS filter → Power Meter

SENSOR

Measurement system prototype and sensors purchase order

October 2024 – January 2025

The project will order a developer to create a system based on the laboratory concept with software control

Tech transfer (workshop in CMU, demo of the prototype)

CCA detection test (Pending samples provided by KKU and Laos Team)

February 2025



COMPLETED

PENDING/ INPROGRESS

Confidential

Biosensing portable platform for clinical sample of Laos CCA patients in various specimens

Collect and verify CCA samples: urine, serum



Budget usage	Budget
Collection of various samples from the patients: healthy, CCA, HCC, and other cancers; materials, volunteer compensation, physician, surgeon, etc.,	\$2500
Identification & evaluation of biomarker in CCA patients: training set	\$1500
Total	\$4000

} Budget plan for year 2

Project Activities: **Workshop on Nov 13-16, 2023 at Vientiane, LAO PDR**



Project Activities: Workshop on June 20-21, 2024 at KKU, Thailand

BAYASITA HOTEL
123 Mittraphap Rd., Muang District,
Khon Kaen 40002, Thailand

ASEAN IVO
13 National Organisations of
ASEAN Institutes of Health (NIH)

OPEN WORKSHOP FOR

**INNOVATION OF PHOTONIC AND
ELECTROCHEMICAL BIOSENSORS FOR
CHOLANGIOCARCINOMA DIAGNOSIS**

Date:
June 20th-21st, 2024

Time:
8:00 am - 5:00 pm



PLEASE JOIN US

REGISTER PROGRAM AGENDA

SPEAKERS

 Prof. Shosuke Kawanishi Suzuka University of Medical Science	 Prof. Tetsuya Kawanishi Waseda University	 Prof. Nipon Theera-Uyompi Director of Biomedical Engineering Institute, CMU
 Assoc. Prof. Chawalit Parojkul Khon Kaen University	 Prof. Somchai Pintaor Khon Kaen University	 Assoc. Prof. Raynoo Thanan Khon Kaen University
 Assist. Prof. Chavis Srichan Khon Kaen University	 Assist. Prof. Chadamas Sakonsinsiri Khon Kaen University	 Dr. Sitthiruk Roytrakul NECTEC
 Dr. Kauchi Akahane National Institute of Information and Communications Technology	 Dr. Noppadon Nuntawong NECTEC	 Dr. Nithi Atthi NECTEC
 Ms. Aye Myat Mon Khon Kaen University	MODERATORS	
	 Dr. Apisit Chaldee Khon Kaen University	 Ms. Phonplias Thongpon Khon Kaen University


Department of Parasitology, Faculty of Medicine, Khon Kaen University, Thailand
This symposium is the output of the ASEAN IVO (http://www.ivo.or.jp/), a project of the ASEAN Institute of Health (AIH) and the ASEAN Institute of Health (AIH) and the ASEAN Institute of Health (AIH) and the ASEAN Institute of Health (AIH).





R&D results: ENKKU-MDKKU; Biosensing platform development based on Raman spectroscopy techniques.

ENKKU: Surface Enhance Raman Spectroscopic (SERS) chip development.



- Received
- 1 Software license
- 2 (Tier 1) Article under peer review [Nature Scientific Reports]
- 3. (Scopus-index) Conference paper to appear in IEEEXplore

Highly-accurate and robust early-stage detection of cholangiocarcinoma using near-lossless S...

CURRENT STATUS
Your submission is in peer review

Progress so far [Show history](#)

- Submission received
- Technical check
- Editorial assignment
- With editor
- Peer review

News about your peer review process

- The editor has invited more than 10 reviewer(s)
- There are 2 reviewer(s) that have accepted to review your manuscript
- The editor has received 1 reviewer report(s)

After the editor has collated and reviewed all the reports they need, which may involve seeking additional reviews, you'll be notified about their decision.



ทะเบียนข้อมูลเลขที่ ว1.011364
คำขอแจ้งข้อมูลเลขที่ 446105

หนังสือแสดงการแจ้งข้อมูลลิขสิทธิ์
ออกให้เพื่อแสดงว่า
มหาวิทยาลัยขอนแก่น
ได้แจ้งข้อมูลลิขสิทธิ์ไว้ต่อกรมทรัพย์สินทางปัญญา

เมื่อวันที่ 5 เดือน สิงหาคม พ.ศ. 2567
ประธานงาน งานนิทรรศการ สักกะผลงาน โปรแกรมคอมพิวเตอร์
ชื่อผลงาน โปรแกรมประยุกต์บนสมาร์ตโฟนและคอมพิวเตอร์สำหรับแยกแยะ
ภาวะมะเร็งท่อน้ำดีผ่านสัญญาณรามานโดยใช้เทคนิคแมชชีนและดีเจเนอเร
นแนหลายความละเอียดร่วมกับระบบเครือข่ายประสาทเทียมเชิงลึก
(Mobile and Desktop Application for Raman Signal Classification
for Cholangiocarcinoma Stage Identification using Multiresolution
Feature Extraction and Deep Neural Networks)

ออกให้ ณ วันที่ 11 เดือน กันยายน พ.ศ. 2567

ลงชื่อ.....
(นางสาวศิริวรรณ นพรัก)
นักวิชาการพาณิชย์ปฏิบัติการ
ปฏิบัติราชการแทนผู้อำนวยการกองลิขสิทธิ์

ACKNOWLEDGMENT

We acknowledge the funding support from NICT, Japan, under the ASEAN IVO 2023 Project, "Innovation of Photonic and Electrochemical Biosensors for Cholangiocarcinoma Diagnosis." Special thanks are extended to Dr. Sirinapa Klungsaeng for her contributions during the initial phase of this work. Collaborations with NECTEC team through Dr. Pitak Eiamchai and Dr. Noppadon Nuntawong are greatly appreciated.

[BMEiCON2024] paper submission result

Dear Pobporn Danvirutai

Congratulations - your paper #BMEiCON2024-010 ("Early-Stage Cholangiocarcinoma Detection Using Surface-Enhanced Raman Spectroscopy and 1D CNN with Discrete Wavelet Transform") has been accepted for oral presentation at the 2024 Biomedical Engineering International Conference (BMEiCON 2024) held in Pattaya, Thailand during November 21-24, 2024.

The reviewing comments associated with this paper (if any) can be found below. Before re-submitting paper, please revise paper according to reviewer comments.



With this letter, we cordially invite you and your co-authors to attend BMEiCON 2024 to present your paper as oral session.

Please submit all final camera-ready papers and the copyright transfer form(s) by October 15, 2024 via <http://edas.info/>. Please make sure that your paper format complied with IEEE express using BMEiCON2024 paper template. BMEiCON2024 paper template and Copyright transfer form can be downloaded from BMEiCON2024 website www.bmeicon.org/bmeicon2024 or Camera-Ready page. <https://www.bmeicon.org/bmeicon2024/index.php/camera-ready>

หมายเหตุ เอกสารนี้มีได้รับรองความเป็นเจ้าของลิขสิทธิ์
ในกรณีมีข้อพิพาทศาลจะเป็นผู้วินิจฉัยชี้ขาดความเป็นเจ้าของลิขสิทธิ์

R&D results: CMU

CMU: Designed and developed photonic sensor device for CCA diagnosis.



Sensing results: Laboratory proof of concept of the prototype

Next step CCA biomarker test

Scientific Contribution:

Presentations at International Conferences:


No:	Paper title:	Author names	Affiliation	Conference name:	The date of the conference	The venue of the conference
1	Early diagnosis of cholangiocarcinoma using surface-enhanced Raman spectroscopy combined with AI in a hamster model	Somchai Pinlaor a,b, Chavis Srichanc, Pobporn Danvirutaid, Kitti Intuyodb,e, Apisit Chaideea,b, Chawalit Pairojkuleb,e, Thatsanapong Pongking b,f, Suppakrit Kongsintaweek b,f, Mati Horprathumg, Pitak Eiamchaig, Saksorn Limwicheang, Noppadon Nuntawongg	^a Department of Parasitology, Faculty of Medicine, and ^b Cholangiocarcinoma Research Institute, ^c Faculty of Engineering, ^d College of Computing, ^e Department of Pathology, Faculty of Medicine, ^f Biomedical Sciences Program, Khon Kaen University, Khon Kaen 40002, Thailand. ^g National Electronics and Computer Technology Center (NECTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand	the 83rd Annual Meeting of the Japanese Cancer Association (JCA2024)	September 19 (Thu.) - 21 (Sat.), 2024	Fukuoka, Japan

Published Journal Papers:

No:	Paper title:	Author names	Affiliation	Journal name:	The publisher of the Journal	The volume number and Pages
1	Early Detection of Cholangiocarcinoma via Surface-Enhanced Raman Scattering using 2D Convolutional Neural Network in Point-of-Care Mobile Application	Chavis Srichan ^{1,2} , Thatsanapong Pongking ³ , Suppakrit Kongsintaweek ³ , Sartra Wongthanavas ⁴ , Somchai Pinlaor ^{3, **, *} , Pobporn Danvirutai ^{4, *}	¹ Department of Computer Engineering, Faculty of Engineering, Khon Kaen University, Khon Kaen 40002, Thailand. ² Department of Biomedical Engineering, Faculty of Engineering, Khon Kaen University, Khon Kaen 40002, Thailand. ³ Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. ⁴ College of Computing, Khon Kaen University, Khon Kaen 40002, Thailand.	Scientific Reports	Nature, Springer	Under review

Poster presentation on JCA 2024

Manuscript submitted



P15-6 P3267

Early diagnosis of cholangiocarcinoma using surface-enhanced Raman spectroscopy combined with AI in a hamster model

Background: Cholangiocarcinoma (CCA), a bile duct cancer, is prevalent in regions like northeastern Thailand and has a high mortality rate due to late diagnosis. We aim to explore early CCA diagnosis using surface-enhanced Raman spectroscopy (SERS) and machine learning, starting with animal models to later applying to humans.

Methods: In a study involving 52 hamsters, 52 were infected with a low-dose and percentage concentration (L5) and served as controls. Researchers collected various biological samples and analyzed them using SERS spectroscopy and machine learning algorithms. Histopathology identified the development of CCA in inflammation, pre-inflammation, and CCA stages.

Results: Chronic inflammation, pre-inflammation, and CCA stages were distinguished at different time points with SERS significantly enhancing Raman signals. Machine learning achieved over 90% accuracy in CCA diagnosis. SERS combined with machine learning offers potential for early CCA screening, serving as a novel, non-invasive method that could be developed into a point-of-care diagnostic tool.

Conclusion: This study was supported by ASEAN IVO, JAPAN, Faculty of Medicine, King Rama 9 University, and other organizations for better cooperation.

Highly-accurate and robust early-stage detection of cholangiocarcinoma using near-lossless S...

CURRENT STATUS

Your submission is in peer review

News about your peer review process

- The editor has invited more than 10 reviewer(s)
- There are 2 reviewer(s) that have accepted to review your manuscript
- The editor has received 1 reviewer report(s)

After the editor has collated and reviewed all the reports they need, which may involve seeking additional reviews, you'll be notified about their decision.

Progress so far [Show history](#)

- Submission received
- Technical check
- Editorial assignment
- With editor
- Peer review

Your submission

Your submission

Title

Highly-accurate and robust early-stage detection of cholangiocarcinoma using near-lossless SERS signal processing with machine learning and 2D CNN for point-of-care mobile application

Type

Article

Journal

Scientific Reports

Submission ID

39df7120-2fb1-4a14-ab82-61d7a75a76c9

Copy Right

ทะเบียนข้อมูลเลขที่ 1.011364
คำขอแจ้งข้อมูลเลขที่ 446105

หนังสือแสดงการแจ้งข้อมูลลิขสิทธิ์
ออกให้เพื่อแสดงว่า
มหาวิทยาลัยขอนแก่น
ได้แจ้งข้อมูลลิขสิทธิ์ไว้ต่อกรมทรัพย์สินทางปัญญา

เมื่อวันที่ 5 เดือน สิงหาคม พ.ศ. 2567
ประเภทงาน วรรณกรรม สิ่งพิมพ์งาน โปรแกรมคอมพิวเตอร์
ชื่อผลงาน โปรแกรมประยุกต์บนสมาร์ตโฟนและคอมพิวเตอร์สำหรับแยกแยะ
ลักษณะเร็นท์น้ำที่ผ่านสัญญาณรบกวนโดยใช้เทคนิคแคชเช่พีเจอร์
แยกหลายความถี่ร่วมกับระบบเครือข่ายประสาทเทียมเชิงลึก
(Mobile and Desktop Application for Raman Signal Classification
for Cholangiocarcinoma Stage Identification using Multiresolution
Feature Extraction and Deep Neural Networks)

ออกให้ ณ วันที่ 11 เดือน กันยายน พ.ศ. 2567

ลงชื่อ.....
(นางสาวศิริวรรณ นพวัถ)

นักวิชาการพาณิชย์ปฏิบัติการ
ปฏิบัติราชการแทนผู้อำนวยการกองลิขสิทธิ์

หมายเหตุ เอกสารนี้มิได้รับรองความเป็นเจ้าของลิขสิทธิ์
ในกรณีมีข้อพิพาทศาลจะเป็นผู้วินิจฉัยชี้ขาดความเป็นเจ้าของลิขสิทธิ์

Signed by DIP-CA

1. **Provided proteomics data:** The accession numbers is ongoing to deposit for ProteomeXchange and JPST003398 for jPOST. Preview.
2. Submitted manuscript on Scientific Reports (under reviewed)
3. International conference on - The 83rd Annual Meeting of the Japanese Cancer Association (JCA)-, on September 19-21, 2024 at Fukuoka, Japan
4. **Manuscript preparation on: INPROGRESS**
 1. **Proteomics identified candidate markers for CCA diagnosis**
 2. **beta-HCG marks for CCA diagnosis**
 3. **Incidence of liver cancer in Lao PDR**

Future works:

Teams	Future works
MDKKU ENKKU BIOTECH NECTEC	<ul style="list-style-type: none"> • Sample collection and Std protein & ab for CMUs' team • Proteins panel discovery • Raman spectrum identification • Construct AI & Machine learning • Transfer technology of SERS and AI for CCA diagnosis to Laos' team
CMU TMEC	<ul style="list-style-type: none"> - Design and develop photonic sensor for CCA diagnosis - Improve reproducibility of photonic sensor
LAO	<ul style="list-style-type: none"> - Sample collection of CCA patients - Evaluate sensor to detect CCA diagnosis

Activity and budget planning in the 2nd year



No	Activities	Budget (US)	Responsibility	Out put
1	<ol style="list-style-type: none"> 1. Sample collection and Std protein & ab for CMUs' team 2. Proteins panel discovery 3. Raman spectrum identification 4. Construct AI & Machine learning 5. Transfer technology of SERS and AI for CCA diagnosis to Laos' team 	21,000	KKU (MD & EN) BIOTECH NECTEC	- Samples of CCA, HCC, metastasis liver and healthy subjects collection, -At least 1 publication -1 patent/pretty patent
2	Optical sensing development: equipment, materials, research exchange at NICT	7,000	CMU	-1 publication
3	Human sample & clinical data collection: Surgery team & pathology team for samples collection, biobank, histopathological study, freezer, equipment, etc.,	4,000	Laos	Team initiation, CCA sample & other cancer sample collection
4	Project meeting or workshop at the end of the 2 nd year	3,000	KKU for all team (CMU-KKU-Laos)	Meeting & conference: 1 session for biosensor for CCA diagnosis
5	Project meeting or workshop at the end of the 2 nd year	3,500	CMU for all team (CMU-KKU-Laos)	Meeting & conference: 1 session for biosensor for CCA diagnosis
6	Project meeting and report (estimate)	1,500	KKU team	Attend on Campodia, 6-7 Nov 2024
	Total	40,000		

Two years time line schedule

Institution	Research activity	2023												2024											
		4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3
MD-KKU, NECTEC, BIOTECH	Supplies & Materials: Animal model setting, equipment, samples collection, Raman spectrometer finger print	█	█	█	█	█	█	█	█	█	█	█	█												
EN-KKU,	SERS chip development : equipment & materials, SERS substrate synthesis and design of portable CCA specific SERS-based sensor, training with NICT				█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█					
CMU	Optical sensing development: equipment, materials, training with NICT													█	█	█	█	█	█	█	█	█	█		
MD-KKU	Surgery team & pathology team for samples collection, biobank, histopathological study, standard method confirmation by ELISA & WB	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	
Lao PDR	Surgery & pathology team management, workshop, training, samples collection, prototype evaluation, team meeting and conference	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	
MD-KKU, EN-KKU, CMU, BIOTECH, NECTEC, TMEC, Laos, NICT	Meeting and conference, transport, report, publication, biosensing prototype								█	█	█	█								█	█	█	█	█	

Thank you



Cancer Center Lao PDR
Est. 2017



Note 1:

1. The number of slides should be around 15 total.
2. The size of your PowerPoint PDF should be no more than 10MB.
3. Please follow the format starting from the next slide.
4. Please delete the first slide (this slide) and upload to the website.

Note 2:

1. You may submit three additional supporting files for a maximum of four files total.
2. Each additional file should be no more than 130MB.
3. Any supporting materials you submit must be saved as PDFs, where possible. This includes PowerPoint presentations, Word documents and Excel spreadsheets. Any audio you submit should be in mp3 format and any video you submit should be in mp4 or mov format.

Note 3:

1. A website for “Submission” is open from September 1, 2024.
(<https://naivo.org/index.php/2024project/papers/instruction>)
2. The website for uploading presentation files will close on October 21, 2024.

Sample setting : MD-KKU,
Discovery and verify CCA diagnosis : EN-KKU, MD-KKU,
NECTEC, BIOTECH




Fig.1 Workspace of project management

Budget plan & purchased plan in the second year

Institution	Equipment's & Chemical
MD-KKU	<ol style="list-style-type: none"> 1. Early biomarker for CCA: Animal sample; verification of proteomic results in the serum and tissue of animal and patients; Raman & data analysis in human samples, test tube, storage box, Eppendorf, autopipette tip, reagent for Raman, std protein, antibody, Chemical and reagent for H&E 2. Collection of various samples from the patients: healthy, BBD, CCA, and other cancers 3. Evaluation of electrochemical & photonic sensor in the patients compared with std method (ELISA & WB); reagent and chemical, WB reagent and chemical
EN-KKU	SERS & AI development for CCA diagnosis
NECTEC	SERS device & data analysis in human samples
BIOTEC	Proteomic technique & data analysis in human samples
CMU-TEMEC	<ol style="list-style-type: none"> 1. Student internship (up to 3 months) at NICT to train for the design, fabrication, and measurement of photonic ship 2. Staff visit to NICT
Lao PDR	Surgery & pathology team management, samples collection, test tube, storage box, Eppendorf, autopipette tip
MD-KKU, EN-KKU, NECTEC, BIOTEC, CMU, TMEC Laos, NICT	Meeting and conference: transport, registration, allowance, etc., <ol style="list-style-type: none"> 1. Face-to-face project meeting at Bangkok (Tentative date Nov 9, 2023, co-location with annual CU-NICT workshop on Nov 10, 2024). 2. Conference or paper publication fee